VEGFA and cancer: Simply blocking VEGF signaling is not enough since the hypoxic and pro-inflammatory tumor microenvironment as well as the heightened mutation rate of cancer cells allows for rapid adaptation to anti-VEGF treatment through the activation of alternative pro-EndoMT “escape pathways” that rescue pathological angiogenesis in a VEGF-independent manner.